This is an exciting time for migraine treatment. Since 2018, several new therapies to both treat migraine and/or prevent migraine attacks have become newly available. These therapies are based on ...

The effectiveness of new migraine treatments has been compared to paracetamol in a new study, which suggests drugs developed in the 1990s should be more widely promoted to patients with the ...

Since its founding in 2018, Olfax has secured an increasing level of funding through grants and awards, boosted in 2022 with awards totaling $35,000 as a regional and top-three statewide winner in the ...

Positive data from three late-stage studies of Lilly's galcanezumab has kept the company in the race to develop a migraine drug in the promising new CGRP ... the six-month treatment period ...

Experts hope the new monoclonal antibody treatments could prove life-changing for many of the millions of people living with migraine, but longer trials are still needed to show this. Prof Peter ...

and there was a "high unmet need for treatment options". Robert Music, chief executive of The Migraine Trust, said the decision "brings new hope" by reducing the pain and length of a migraine attack.

Nevertheless, a substantial number of migraine-affected individuals are unresponsive to triptans, and such therapy can also lead to an array of adverse effects. A new class of antimigraine drugs ...

The pain may start out as mild. But without treatment, it can become moderate to severe. Migraine pain most commonly affects the forehead area. It’s usually on one side of the head but can occur ...